Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

NEOVAX

Vaccine (Peptide vaccine) · Immune activation, directed at patient-specific tumor neoantigens

Phase 1 Most advanced trial
1 Registered trials

What is NEOVAX?

NEOVAX is a personalized neoantigen vaccine given as an injection under the skin. It is designed to direct the immune response against patient-specific tumor neoantigens and is studied in melanoma, including metastatic melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Targets
patient-specific tumor neoantigens (antigen)
Mechanism
Immune activation, directed at patient-specific tumor neoantigens
Therapy area
Oncology
In trials of
CLDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04930783 Phase 1 Melanoma Active not recruiting CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MelanomaMetastatic Melanoma

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.